American College of Rheumatology

Type: Organization
Name: American College of Rheumatology
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Multiple Osteonecrotic Lesions Mimicking a Piano Keyboard in the Spine of a Patient With Catastrophic Antiphospholipid Syndrome

Clinical ImagesSeung Min Jung MD, Ji Hyeon Ju MD, PhD, Seung-Ki Kwok MD, PhD, Kyung-Su Park MD, PhD and Sung-Hwan Park MD, PhDArticle first published online: 26 SEP 2014DOI: 10.1002/art.38712Copyright © 2014 by the American College of RheumatologyIss ... [Published Arthritis & Rheumatism - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Three-Year Clinical Outcome Following Baseline Magnetic Resonance Imaging in Anti–Citrullinated Protein Antibody–Positive Arthralgia Patients: An Exploratory Study

Concise CommunicationYoony Y. J. Gent MD 1 , Marieke M. ter Wee MSc 1 , Nazanin Ahmadi MD 1 , Cornelis van Kuijk MD, PhD 1 , Alexandre E. Voskuyl MD, PhD 1 , Conny J. van der Laken MD, PhD 1 , Cristina Dowling MD 2 , Lotte A. van de Stadt MD, PhD 2 and ... [Published Arthritis & Rheumatism - Sep 26 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 3 reports

NIH Launches Major Coordinated Effort to Understand Lupus and RA

Weary of trying to pull together all the information about disease pathways into a sensible description of autoimmune dysfunction? So are the researchers themselves, and they've launched a massive coordinated effort to make sense of it all. They'll start ... [Published Consultant Live - Sep 26 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 1 reports

Novartis plans secukinumab filings next year in psoriatic arthritis after positive late-stage results

Novartis said Thursday that two Phase III studies of secukinumab in patients with psoriatic arthritis met their primary and key secondary endpoints, with regulatory filings in this indication planned for 2015. The company noted that the drug, also known ... [Published FirstWord Pharma - Sep 25 2014]
First reported Sep 22 2014 - Updated Sep 23 2014 - 1 reports

Broad physician coalition urges Congress to extend Medicaid pay parity

PUBLIC RELEASE DATE: 22-Sep-2014(Washington) – The efforts and leadership of Senators Sherrod Brown (D-Ohio) and Patty Murray (D-Wash.) to ensure access to vital primary care services were lauded yesterday by the American College of Physicians (ACP) and ... [Published EurekAlert! - Sep 22 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 1 reports

Hypersensitivity to Non-Painful Events May be Part of Pathology in Fibromyalgia

New research shows that patients with fibromyalgia have hypersensitivity to non-painful events based on images of the patients' brains, which show reduced activation in primary sensory regions and increased activation in sensory integration areas. Findings ... [Published Pro Health Network - Sep 16 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

The biological basis for clinical heterogeneity in childhood arthritis

AbstractObjective. Childhood arthritis encompasses a heterogeneous family of diseases. Significant variation in clinical presentation remains despite consensus-driven diagnostic classifications. Developments in data analysis provide powerful tools for ... [Published Arthritis & Rheumatism - Sep 08 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Daiichi Sankyo initiates Phase III rheumatoid arthritis trial in Japan

Daiichi Sankyo Company, Limited, a manufacturer of pharmaceuticals, has initiated a Phase III trial of CHS-0214, an investigational etanercept biosimilar, for rheumatoid arthritis, or the RApsody trial, in Japan. Daiichi Sankyo is a co-sponsor of this ... [Published Individual.com - Sep 05 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Expression of the Dermatomyositis Autoantigen TIF1γ in Regenerating Muscle

AbstractObjective . Autoantibodies against TIF1γ are found in many patients with dermatomyositis (DM). Although TIF1γ is known to play a role in the differentiation of other tissues, its functional role in muscle regeneration has not been elucidated. ... [Published Arthritis & Rheumatism - Sep 03 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Meta-analysis of assay sensitivity and study features in clinical trials of pharmacologic treatments for osteoarthritis pain

ABSTRACTObjective: The objective of this study was to identify patient, study, and site factors associated with assay sensitivity in clinical trials of pharmacologic treatments for osteoarthritis (OA) pain.Methods: We examined associations between study ... [Published Arthritis & Rheumatism - Sep 03 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

RA: Effect of 'Complete Disease Control' on Pain, Function

A retrospective analysis of pooled data from 3 randomized trials of adalimumab plus methotrexate for treatment of rheumatoid arthritis (RA) showed that patients who achieved "complete disease control" (CDC) at week 26 had better pain, fatigue, and health ... [Published General Medicine eJournal - Sep 03 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Protalex Announces Acceptance of Abstract Highlighting Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients at the 2014 American College of Rheumatology Annual Meeting

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that an abstract highlighting results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation ... [Published Business Wire Health News - Sep 03 2014]

Quotes

...has reported positive 58 week follow up data from its BOW015 efficacy and safety trial comparing BOW015, a biosimilar infliximab, to Remicade. "The open label phase of the study was designed to provide data on long term safety and durability of response as well as long term safety for Remicade responders switching to BOW015. This data suggests the patients can safely be started and maintained on BOW015 and that patients can be safely switched from Remicade to BOW015" said Michael Wyand, DVM, PhD, senior vice president of clinical, regulatory and manufacturing
...First, the immune system develops antibodies that attack the body's own DNA, then that activated immune system attacks the kidneys," Mohan said. "We found that CDDO may block both of these steps."
...related subspecialty physicians for many of this nation's most vulnerable citizens," pointed out David A Fleming, MD, MA, FACP, president of ACP. "It will ensure sufficient payment for primary care services and vaccinations, and to the physician specialties and subspecialties that deliver them, is essential to providing access for the 65 million women, men, adolescents and children enrolled in Medicaid."
...Robert Terkeltaub , MD, Principal Investigator for Revive. "There remains significant unmet need for novel therapies targeted towards preventing and/or treating gouty inflammation and lowering serum uric acid levels. The majority of gout patients have comorbidities that increase adverse events and potential drug interactions of the current generation of therapeutics for gout. Hence agents that can successfully control gout, without inducing more drug-related gout flares and adverse events, will be particularly welcome options in managing patients with gout. Revive's drug candidate, REV-002, merits investigation for clinical care and outcomes in gout patients. I look forward to playing a substantial role in design, data interpretation, and continuing evaluation of this evolving clinical trial program."

More Content

All (89) | News (80) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Cytotoxic Agents in Sarcoidosis: Which One to C... [Published General Medicine eJournal - Sep 29 2014]
Can Online Cognitive Behavioral Therapy Help Fi... [Published Pro Health Network - Sep 28 2014]
Multiple Osteonecrotic Lesions Mimicking a Pian... [Published Arthritis & Rheumatism - Sep 26 2014]
Three-Year Clinical Outcome Following Baseline ... [Published Arthritis & Rheumatism - Sep 26 2014]
Incorrect Institutional Affiliation of Author i... [Published Arthritis & Rheumatism - Sep 26 2014]
Journals watch: Colchicine for gout, CT in depr... [Published GP Online - Sep 26 2014]
EPIRUS Reports Positive 58 Week Follow up Data ... [Published Individual.com - Sep 26 2014]
NIH Launches Major Coordinated Effort to Unders... [Published Consultant Live - Sep 26 2014]
Secukinumab Meets Key Objectives in Phase III T... [Published PT Community - Sep 25 2014]
Plant Extract may Lead to Development of New Dr... [Published MedIndia - Sep 25 2014]
Soon, plant extract may be used for treating lu... [Published Business Standard India - Sep 25 2014]
Novartis plans secukinumab filings next year in... [Published FirstWord Pharma - Sep 25 2014]
Broad physician coalition urges Congress to ext... [Published EurekAlert! - Sep 22 2014]
The Pathogenesis, Diagnosis and Treatment of Lu... [Published General Medicine eJournal - Sep 19 2014]
Revive Therapeutics : Names Dr. Robert A. Terke... [Published 4 Traders - Sep 17 2014]
Fibromyalgia: Patients Hypersensitive to Nonpai... [Published American Journal of Public Health - Sep 17 2014]
Revive Therapeutics Taps Dr. Robert A. Terkelta... [Published Individual.com - Sep 17 2014]
Managing arthritis [Published Louisiana Weekly - Sep 17 2014]
Mariel Therapeutics Appoints World Leading Expe... [Published Pharmacy Choice - Sep 16 2014]
Broad Physician Coalition Urges Congress to Ext... [Published Noodls - Sep 16 2014]
Hypersensitivity to Non-Painful Events May be P... [Published Pro Health Network - Sep 16 2014]
Hypersensitivity to non-painful events could be... [Published Examiner.com - Sep 16 2014]
Altered white matter integrity in corpus callos... [Published Arthritis & Rheumatism - Sep 15 2014]
Altered cellular and humoral immunity to varice... [Published Arthritis & Rheumatism - Sep 15 2014]
Anakinra use during pregnancy in patients with ... [Published Arthritis & Rheumatism - Sep 15 2014]
Lupus Research Institute Launches NYC's First L... [Published RCL Advisors - Sep 15 2014]
Lupus Research Institute Launches NYC's First L... [Published Wall Street Select - Sep 15 2014]
Mariel Therapeutics Appoints World Leading Expe... [Published InvestorPoint.com - Sep 15 2014]
Fibromyalgia may Involve Hypersensitivity to No... [Published MedIndia - Sep 15 2014]
33http://www.currencyonline.com/tbl/ 65438479 [Published Student Village - Sep 15 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Politics: Why are MS DMTs such poor value for m... [Published Multiple Sclerosis Research - Sep 05 2014]
What can we do about rationing of drugs in the NHS? #MSPolitics #MSBlog #MSResearch "How do you feel when someone says that it only worth paying £36,000 for one quality adjusted health year (QALY) for someone with MS? If a treatment costs more than ...
Protalex Announces Acceptance of Abstract Highl... [Published Business Wire Health News - Sep 03 2014]
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that an abstract highlighting results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation ...
Rheumatologists Agree That the American College... [Published PR Newswire: General Business - Apr 30 2014]
BURLINGTON, Mass., April 30, 2014 /PRNewswire/ --Decision Resources Group finds that, when asked to select the top three most persuasive end points when prescribing a new drug for psoriatic arthritis (PsA), the highest percentages of surveyed United ...
Sprifermin Offers Benefit For Cartilage Loss Fr... [Published Scientific Blogging - Apr 17 2014]
In a new study in patients with osteoarthritis (OA) of the knee, at 12 months, total femorotibial cartilage thickness loss was reduced in sprifermin (recombinant human fibroblast growth factor 18)-treated knees compared to placebo-treated knees, with ...
Rheumatology Network Features Coverage of Ameri... [Published PR Newswire: General Business - Apr 16 2014]
NORWALK, Conn., April 16, 2014 /PRNewswire/ -- UBM Medica US announces that Rheumatology Network, a leading online community for rheumatologists, presents news about treatment of childhood joint diseases from exclusive coverage of the American College ...
1 2

Press Releases

sort by: Date | Relevance
Apricus Biosciences Announces Multi-Year Partne... [Published GlobeNewswire: Acquisitions News - Aug 08 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.